Peptides clinical trials
How each study uses Peptides is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Peptides studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2005 (1)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 7
Adilia Hormigo (1) · Patrick Ott, MD, PhD (1) · Egymedicalpedia (1) · Nina Bhardwaj (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Dr. Nina Bhardwaj (1) · Ryazan State Medical University (1) · University of Yamanashi (1)
Often tested with
Tested in the same studies.
Poly ICLC (2) · Selicrelumab (1) · Dendritic Cell (1) · Monatide (IMS 3015) (1)
Studies
Open first, then newest update. How each study uses Peptides is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis.RecruitingNot applicableRyazan State Medical UniversityNCT05933720Written as Polypeptides
- Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat GlioblastomaActive, not recruitingPhase 1Adilia HormigoNCT03223103Written as Peptides
- A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in MelanomaCompletedPhase 1Patrick Ott, MD, PhDNCT01970358Written as Peptides
- Evaluation of the Effect of Self-Assembling Peptide P11-4CompletedPhase 1EgymedicalpediaNCT05667545Written as Peptide
- Safety and Immunogenicity of Personalized Genomic Vaccine to Treat MalignanciesCompletedPhase 1Nina BhardwajNCT02721043Written as Peptides
- Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100CompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT01008527Written as Peptides
- Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma VaccineCompletedPhase 1Dr. Nina BhardwajNCT00124124Written as KLH; Peptides; Dendritic Cells
- A Study With Peptide Vaccination in Treating Patients With Esophageal CancerStatus unknownPhase 2University of YamanashiNCT00995358Written as peptide
Given beside what is tested · 2 — Peptides is usual care or a partner of the new treatment
- Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV MelanomaCompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT01176474Written as gp100:280-288 (288V)
- A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in MelanomaStatus unknownPhase 1Xiangya Hospital of Central South UniversityNCT04072900Written as Peptide